TGFB1 and cancer: It has been shown that TGF‐β expressed on the surface of cancer‐derived EVs triggers the TGF‐β/SMAD3 signaling pathway in recipient fibroblasts, which induces the expression of a myofibroblast‐like phenotype (α‐SMA, FGF2)146; EV also generates CAFs through a nonclassical fibronectin‐dependent pathway.147